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Abstract 
Various efflux transporters, such as P-glycoprotein (P-gp) are now widely accepted to have profound 
influence on the disposition of substrates. Nevertheless, there is paucity of information about their 
expression and functionality in the pain relevant tissues (such as brain, spinal cord and dorsal root ganglia 
(DRG)) across various species. Therefore, our attempts were directed at evaluating P-gp expression in these 
tissues to understand its effect on the central nervous system (CNS) disposition. As a means of 
characterizing the normal tissue distribution of P-gp, immunohistochemistry was performed with two 
antibodies (C219 and H241) directed against different epitopes of MDR1 gene. Notable expression of P-gp 
was detected in the DRG of Sprague Dawley rat, Beagle Dog, Cynomolgous monkey as well as human. The 
expression of P-gp was observed in the CNS tissues with evident species differences, the expression of P-gp 
in human brain and spinal cord was lower than in rats and dogs but relatively comparable to that in 
monkeys. However, no species related differences were seen in the expression at the DRG level. Double-
labelling using an antibody against a marker of endothelial cells confirmed that P-gp was exclusively 
localized in capillary endothelial cells. This study highlights the cross species similarities and differences in 
the expression of P-gp and thus serves as a vital step in understanding the translation of exposure of P-gp 
substrates to human. 
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Introduction 
Developing CNS therapeutics has been one of the most challenging areas of drug discovery and 
development in the pharmaceutical industry. This has been primarily due to the restricted delivery of the 
drug across the physiological barriers (e.g. the blood brain barrier etc.) and also due to the lack of 
understanding of the differences in expression of proteins affecting the transport of drugs [1]. Transport of 
molecules across these barriers is a highly complex phenomenon driven by passive diffusion alone or in 
concert with efflux or influx transport [2]. ABC efflux transporters such as p-glycoprotein (P-gp) are well 
known to have profound influence on brain concentration of their substrates [3]. Studies on understanding 
the contribution of P-gp efflux on CNS exposure have been largely conducted in rodents, studies in human 
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and monkey have been sparse; as a consequence, there is limited knowledge about species differences in 
the efflux of drug molecules across the blood-brain barrier. Syvänen et al., have reported that some P-gp 
substrates were effluxed out of the rodent brain but not by the primate brain [4]. The observed differences 
in brain exposure of these compounds in rodents vs primates could be attributed to existence of species 
difference in P-gp function. There have been some reports of species differences in the affinity of P-gp 
substrates amongst cell lines transfected with P-gp from different species [5-8]. These results indicate 
species differences in P-gp function despite the high degree of homology in the amino acid content across 
species.  In vivo evidence for species differences in P-gp function has been demonstrated by Cutler et al., 
who found that higher concentrations of the P-gp inhibitor GF-120918 were needed in guinea pigs than in 
rats to achieve the same increase in brain concentrations of an undisclosed P-gp substrate [9]. Besides 
differences in substrate affinity, differences in P-gp expression levels could also result in differences in P-gp 
transport capacity. To our knowledge, there have been no reports on the differences in expression 
patterns of P-gp in brain tissues across various species. In addition, functionality and expression of P-gp at 
blood spinal cord barrier is controversial and influence of P-gp on spinal cord exposure has not been widely 
studied [10-13]. Because the site of action for some pain indications are located in spinal cord and dorsal 
root ganglia (DRG), the knowledge gained from the microenvironment of the spinal cord DRG could be 
potentially harnessed to understand the role of P-gp in manipulating drug exposure to target proteins 
expressed in these regions and to aid in the translation of efficacy data of compounds from animals to 
human [14, 15]. Thus, in this study our attempts were directed at evaluating the expression of P-gp in the 
brain, spinal cord and DRG of various species. Rat, dog and monkey were selected for evaluation because 
they are widely used preclinical species. Expression of P-gp in the tissues of the above mentioned species 
was evaluated using indirect immunohistochemistry and the cellular localization was determined using 
immunofluorescence and confocal microscopy.    
Experimental  
Animal Tissues 
Tissues were collected from naïve male Sprague Dawley rats, male Beagle dogs and male Cynomolgus 
monkeys. Tissues were collected from at least three different animals for all species evaluated. All 
procedures were carried out as per the institutional Animal Care and Use Committee as well as Animal 
Research: reporting of In Vivo Experiments (ARRIVE) guidelines. Briefly, prior to tissue excision dogs were 
anaesthetised with ketamine, xylamine and euthanyl. The tissues were excised and immediately frozen in 
liquid nitrogen. Cynomolgus monkey (Macaca fascicularis) weighed between 2-3 kg. One of the three 
monkeys was naïve, the other two monkeys were given a washout period of 4 weeks prior to tissue 
excision. For tissue excision, monkeys were anaesthesized by ketamine and sodium pentobarbital prior to 
being scarified. Tissues were harvested and stored in liquid nitrogen and subsequently stored at -80 °C. 
Transverse tissue sections were cut at 14 µm using a Microm HM 500 OM cryostat (Microm, Walldorf, 
Germany) after embedding the tissues in tissue freezing medium (Jung, Nussloch, Germany).  
Human Tissues 
Human tissues were obtained from the University of Minnesota as per the institutional ethical 
guidelines and the Code of Ethics of the World Medical Association (Declaration of Helsinki). Tissues were 
collected from two male and three female individuals with age ranging between 18-56 years. None of the 
individual had reported neurological condition. Tissue sectioning was performed as outlined in the previous 
section. 
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Immunohistochemistry 
Expression of P-gp protein was mapped using indirect immunohistochemistry. All the experiments were 
conducted on histologically well preserved fresh frozen tissues. Two distinct antibodies against P-gp were 
employed as primary antibodies, namely, C219 (mouse monoclonal antibody) and H241 (rabbit anti-human 
polyclonocal antibody) (Calbiochem, San Diego, CA, USA and Santa Cruz Biotechnologies, Dallas, Texas, 
USA, respectively). Frozen sections were thawed for 5 min followed by fixation with ice cold acetone for 5 
min. Tissue sections were washed 3 times in 0.1 M TBS (tris buffered saline) and then quenched with 0.5 % 
hydrogen peroxide. This was followed by washing steps with 0.1 M TBS, then sections were subsequently 
blocked with blocking buffer (5 % normal goat serum) for 1.5 h. The blocking medium was removed and 
sections were incubated overnight with appropriately diluted primary antibody. As a negative control, the 
primary antibodies were replaced by serum to determine the degree of artifactual labelling by the 
secondary antibodies (biotinalyted goat anti-mouse IgG or biotinalyted goat anti-rabbit IgG, Vector 
Laboratories, Burlingame, CA, United States). Additionally, the primary antibody was incubated with 
blocking peptide to delineate non-specific labelling by the primary antibody. Sections were then rinsed 
three times with 0.1 % BSA (bovine serum albumin) in 0.1 M TBS, and then incubated for 30 min with 
avidin-biotinylated horseradish peroxidase complex (Vectastain, Vector laboratories, Burlingame, CA, 
United States). Diaminobenzidine (Immpact DAB, Vector laboratories, Burlingame, CA, United States) was 
used as a chromogen. After the treatment, sections were washed with distilled water, dehydrated with 
ethanol (50, 70, 95 and 100 %) and defatted in xylene and mounted with Permount mounting medium. 
Bright field images were captured using a Leica DM4000B microscope (Leica Microsystems, Wetzlar, 
Germany).  
Immunofluorescence and confocal microscopy 
Cellular localization of P-gp was assessed by immunofluorescent co-localization with the C219 antibody 
and an antibody raised against endothelial cell marker, Von-Willebrand factor (VWF, rabbit polyclonocal 
antibody, Abcam, Cambridge, United Kingdom). For double labelling, tissue sections were allowed to air dry 
for approximately 5 min. They were then fixed with ice cold acetone (4 °C) for 5 min. After being rinsed 
with 0.1 M TBS thrice, slides were incubated with 0.5 % hydrogen peroxide for 10 min at room 
temperature. Slides were rinsed again and incubated with blocking buffer (5 % normal goat serum) for 
1.5 h at room temperature. C219, P-gp primary antibody was added to each slide followed by overnight 
incubation at 4 °C. The next day, slides were washed slides with 0.1 % BSA in 0.1 M TBS and then incubated 
with secondary antibody (Alexa 488 goat anti-mouse, Vector Laboratories, Burlingame, CA, United States) 
for C219 for 2 h. Subsequently, all sections were rinsed with 0.1 % BSA in 0.1 M TBS, blocked with blocking 
buffer (5 % normal donkey serum) for Von Willebrand factor (VWF) antibody for 1.5 h at room 
temperature and then incubated with VWF primary antibody for 4.5 h at 4 °C.  Slides were rinsed with 
0.1 % BSA in 0.1 M TBS and subsequently incubated with secondary antibody for VWF (Cy-3 conjugated 
donkey anti-rabbit, Jackson Laboratories, West Grove, PA, United States) for 45 min. Slides were 
coversliped using Aqua polymount after being rinsed with 0.1% BSA in 0.1 M TBS. Fluorescent signals from 
double labelled sections were detected and recorded using a confocal microscope (Zeiss confocal laser 
scanning TCS SPE microscope, Carl Zeiss Microscopy GmbH, Jena, Germany). Post-acquisition all 
fluorescent images were analysed by ImageJ analysis software for intensity and area of P-gp 
labelling/expression.  
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Results and Discussion 
The published literature on the expression of P-gp in the CNS largely focuses on its expression in the 
brain tissue; consequently, there is a paucity of information on its expression in other CNS tissues. In 
particular, the reports on the expression of this trans-membrane efflux pump in the spinal cord and DRG 
have been sparse. The lack of understanding of species differences in expression and functionality of 
transporters can serve as a bottleneck in the translation of drug disposition from preclinical species to 
human, particularly, for compounds with the site of action in CNS [16]. Therefore, in an attempt to 
examine species differences in P-gp expression in various pain relevant tissues, we have looked at the 
detailed micro-anatomic localization of P-gp in the normal brain, spinal cord and DRG tissues of rat, dog, 
monkey and human by using immunohistochemistry, immunofluorescence and confocal microscopy. To 
the best of our knowledge, this is the first report in the literature wherein expression of P-gp has been 
shown in the DRG and spinal cord across several species. Nonetheless, expression of P-gp in various tissues 
has been examined previously by immunohistochemistry and several monoclonal antibodies have been 
described in the literature for immunohistochemical detection of its internal or external epitopes [17-19]. 
In this study, antibodies recognizing two distinct epitopes were used to minimize false-positive results due 
to binding of antibody to proteins with similar epitopes as well as minimize false-negative results from the 
failure of antibody binding due to inadequate tissue processing. We have selected C219 as one of the 
antibodies, because it is one of the most widely used antibody for P-gp immunodetection in both research 
and diagnosis [20, 21]. It recognizes amino acid sequence VQEALD of the cytoplasmic region of the protein, 
which is conserved in all cytosolic domains of P-gp from rodents to human [20, 22, 23]. H-241, a polyclonal 
antibody that recognizes amino acids 1040-1280 at the P-gp C-terminal cytoplasmic domain of human, 
mouse and rat origin was another antibody selected for this study. The specificity of both antibodies has 
been shown by manufacturers using western blotting, immunoprecipitation and immunohistochemistry. 
We have additionally validated the specificity of these antibodies by testing in multidrug resistant cell lines 
(MDR1-MDCK and DLD-1).  
A brown immunoreactive labelling (Figure 1) representing presence of P-gp protein was formed by 
reaction of diaminobenzidine chromogen with horseradish peroxidase complexed to C219 and H241 
antibodies. The pattern of brown staining in the tissue sections was considered to be reflective of presence 
of P-gp protein in tissues. Overall expression of P-gp was found to be similar with both antibodies in all 
species and tissues examined, suggesting absence of both false-positives and negatives (data not shown). 
In negative controls, wherein primary antibody was omitted or when the blocking peptide was used, P-gp 
labelling was not observed (data not shown). This finding together with similar labelling by C219 and H241 
antibodies, indicate absence of non-P-gp specific imunnolabelling. For the simplicity of presentation we 
have reported results of only C219 antibody in the figures. The immunohistographs of the DRGs and spinal 
cord sections showed prominent labelling of P-gp protein in the microvessels (Figure 1). The level of 
expression of P-gp in DRG appeared to be consistent across rat, dog, monkey and human as seen in Figures 
1a to 1d. Immunoreactivity in the spinal cord was uniformly distributed in all the lamellas of the spinal cord 
with no specific expression pattern (Figures 2a to 2d). Spinal cord sections from thoracic, lumbar and sacral 
regions were examined and regional differences were not detected (data not shown). However, grey 
matter of the spinal cord had relatively higher P-gp expression compared to the white matter. We have 
also assessed P-gp expression in the brain of rat, dog, monkey and human. P-gp was expressed in the 
cortical tissues of all species (Figures 3a to 3d) as has been reported previously [24, 25]. The localization of 
P-gp in the brain is controversial with some studies suggesting endothelial expression [24, 25], while others 
reporting expression in the astrocytes or glial cells [26-28]. Nonetheless, even by using antibodies against 
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distinct P-gp epitopes (C219 and H241), immunoreactivity was exclusively detected in capillary endothelial 
cells; neuronal expression of P-gp in the brain tissue was not observed in the species evaluated in the 
present study. Distribution of P-gp in the microvessels was also confirmed by immunofluorescence 
technique (Figure 3). The observation regarding endothelial localization of P-gp could be due probably due 
to the fact that the tissues used in the present study were from healthy animals and non-diseased human 

























Figure 1. Distribution of P-gp in Sprague Dawley rat (1a, 2a, 3a, 4a, 5a, 6a), Beagle dog (1b, 2b, 3b), 
Cynomolgus monkey (1c, 2c, 3c) and human (1d, 2d, 3d) dorsal root ganglia, spinal cord and brain cortex as 
determined by immunohistochemical staining. C219 was used a primary antibody and biotinylated goat anti-
mouse IgG was used as a secondary antibody. Images 1a to 3d were acquired at 10X, while 4a to 6a were 
captured at 40X. Data are representative of images captured for each species and tissue (n = 3).  Arrows 
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Immunofluorescence and confocal microscopy were done to understand the micro-anatomical 
localization of P-gp in the tissues, mainly localization in endothelial cells was evaluated. For this purpose, 
endothelial cells were labelled by VWF antibody (Cy-3 fluorophore) and P-gp by C219 antibody (Alexa 488 
fluorophore) and images were acquired at wavelengths specific to both fluorophores. Rich distribution of 
P-gp was observed in the microvessels of various CNS tissues by immunofluorescence imaging. As seen in 
Figures 2 and 3, the green fluorescent signal from the labelling of P-gp (C219) and red fluorescent signal 
from endothelial cells labelling (VWF) overlayed remarkably well, suggesting largely endothelial expression 
of P-gp. The analysis of the acquired images indicated approximately 95 % of all endothelial cells were 
labelled by P-gp antibodies in both brain and spinal cord. We did not observe any marked changes in the 
microvessel localization of P-gp with species. However, as evidenced by intense labelling in the 
immunohistographs, the highest level of P-gp expression in the microvessels was observed in the DRG 
tissues of all species examined (Figures 2c, 2f & 2i). 
 
     
 
     
 
     
Figure 2. Confocal microscope images of fresh frozen Human tissues labelled with C219 and VWF antibodies 
for P-gp and endothelial cells, respectively. Cy-3 goat anti-mouse was used a secondary antibody for P-gp and 
Alexa-Fluor 488 goat anti-rabbit for endothelial cells. The green panel (left) is indicative of P-gp expression in 
the tissues, while the red panel (middle) displays endothelial cell expression. The right panel is the overlay of 
both red and green signals demonstrating co-localization. Images were acquired at 10 x. Data are 
representative of images captured for each tissue (n = 3). 
Brain (P-gp) Brain (VWF) Brain (Overlay) 
Spinal cord (P-gp) Spinal cord (VWF) Spinal cord (Overlay) 
DRG (P-gp) DRG (VWF) DRG (Overlay) 
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Regional differences were observed within the brain cortex in all species, with the grey matter 
exhibiting higher protein levels relative to the white matter. These regional differences are considered to 
be primarily due the extent of vascularisation of these regions as can be seen from Figures 2 and 3. The 
intensity and area of labelling in the CNS tissues evidently decreased from rat to human. For instance, the 
expression of P-gp in the brain cortex was relatively higher in rat than in dog followed by monkey and 
human. It is important to note that P-gp expression in human and monkey was comparable. A similar trend 
was observed in the spinal cord expression of P-gp. Interestingly, there were no species differences in the 
P-gp expression in the DRG.  
 






Figure 3. Fluorescence images of fresh frozen Human tissues labelled with C219 and VWF antibodies, acquired 
with a confocal microscope at 40x. The green signal is indicative of P-gp labelling in the tissues, while the red 
signal is for endothelial cell expression. The overlay of the two signals is shown in the right panel.  
Conclusions 
In this study we have examined the expression and distribution of P-gp in the pain relevant tissues of 
species widely employed in preclinical research namely Sprague Dawley rat, Beagle Dog, Cynomolgous 
monkey and have compared to that in human. We have also shown that P-gp is expressed in the DRG and 
spinal cord, and that there are species specific and regional differences in P-gp expression in the brain 
cortex and spinal cord. The findings of this study serves as a step forward in understanding species 
differences in transporter expression and may help build our understanding of the translation of drug 
exposure and efficacy from preclinical species to human.  
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